๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)

โœ Scribed by N. Forestier; D. Larrey; P. Marcellin; Y. Benhamou; D. Guyader; W. Bradford; S. Porter; A. Patat; R. Rouzier; S. Zeuzem

Book ID
117377096
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
51 KB
Volume
50
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Antiviral activity of telaprevir (VX-950
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
โœ Nicole Forestier; Hendrik W. Reesink; Christine J. Weegink; Lindsay McNair; Tara ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 202 KB

Telaprevir (VX-950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. The present study evaluated viral kinetics and safety during dosing with telaprevir alone and in combination with peginterferon alfa-2a for 14 da

R1626 plus peginterferon Alfa-2a provide
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
โœ Paul J. Pockros; David Nelson; Eliot Godofsky; Maribel Rodriguez-Torres; Gregory ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 586 KB

R1626, a prodrug of the hepatitis C virus (HCV) RNA polymerase inhibitor R1479, showed time-dependent and dose-dependent reduction of HCV RNA levels in a previous study. The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a ุŽ